Compare Citius Pharmaceuticals Inc (CTXR) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Starbucks Corp trades at $106.09 (market cap $121.00B). The key difference: Starbucks Corp is far larger — about 8265× Citius Pharmaceuticals Inc's market cap, and Starbucks Corp pays a 2.34% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SBUX | |
|---|---|---|
Market Cap | $14.64M | $121.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $107.34 |
52-Week Low | $0.53 | $78.46 |
Enterprise Value | $10.86M | $143.69B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Starbucks (SBUX) trades at $107.34, up 1.25% on the day, with a bullish technical signal from moving averages and near the consensus price target of $108.31. Recent Q2 2026 results showed revenue of $9.53B and EPS beat expectations, while the company focuses on cost-cutting through AI initiatives. The stock exhibits strong support at $107 and faces resistance at $108.
The outlook is cautiously optimistic with analyst consensus leaning buy (47.46%), but high P/E of 81.94 and declining net income margins pose valuation concerns. Key risks include execution of AI cost savings and competitive pressures, while dividend growth and loyalty program strength offer stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
